Emerald Health Pharmaceuticals Inc.
5910 Pacific Center Blvd., #320
San Diego, CA, 92121
Phone: (858) 352-0622
Emerald Health Pharmaceuticals Inc. (“EHP” or “the Company”) is a clinical-stage biotechnology company developing novel proprietary therapeutic molecules to treat various neurodegenerative, autoimmune, inflammatory, and fibrotic diseases with no current cure. The Company’s pipeline includes: EHP-101, initially for the treatment of systemic sclerosis (SSc) and multiple sclerosis (MS), and EHP-102, initially for the treatment of Parkinson’s disease (PD) and Huntington’s disease (HD). Most current treatments for neurodegenerative and autoimmune diseases take aim at addressing symptoms but provide no disease modifying capabilities. This is because they address only part of the multiple biological processes that influence the disease. EHP’s product candidates are new chemical entities (NCEs), created through Rational Drug Design based on the molecular architecture of the non-psychoactive cannabinoids, cannabidiol (CBD) and cannabigerol (CBG). Due to the unique molecular structure of the new molecules, these candidates display a multifaceted mechanism of action designed to affect the key biological processes associated with the conditions, with the goal of exerting disease-modifying properties and potentially reversing disease progression. Furthermore, while EHP’s product candidates are based on cannabinoid architecture, the Company’s active ingredient in its lead product candidate is not classified as a controlled substance under federal law. In addition, EHP’s novel technology does not require extraction of molecules from the cannabis plant, allowing the Company to patent their novel molecules—something that companies using basic cannabinoids cannot do because natural molecules cannot be protected. The Company has secured 25 granted patents and 19 pending patents covering their portfolio of 25 unique molecules and is differentiated by its efforts to develop novel therapies through the interactions with the body’s physiologic receptors and pathways, which are targets for many diseases.
* The Corporate Snapshot was last updated on November 30, 2021.